Currently, there are numerous clinical trials undergoing that study various landscapes – from the use of newer or repurposed chemotherapeutics, to the introduction of newer immunotherapeutic agents, antibody-drug conjugates, TCR-T cell therapy and the study of mDC3/8-KRAS cancer vaccines, among others. This evidence concerns the gene KRAS and cancer.